Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032 Life Science Investing
Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression Life Science Investing
Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference Life Science Investing
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights Life Science Investing
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities Life Science Investing
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression Life Science Investing
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression Life Science Investing
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression Life Science Investing
